Get the Stockscreener App
7.15
33.40%
1.79
After Hours:
7.09
-0.06
-0.84%
Ataibeckley Inc stock is traded at $7.15, with a volume of 165.66M.
It is up +33.40% in the last 24 hours and up +72.71% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$5.36
Open:
$7.065
24h Volume:
165.66M
Relative Volume:
16.53
Market Cap:
$2.63B
Revenue:
$3.49M
Net Income/Loss:
$-663.48M
P/E Ratio:
-3.1938
EPS:
-2.2387
Net Cash Flow:
$-115.08M
1W Performance:
+34.15%
1M Performance:
+72.71%
6M Performance:
+96.43%
1Y Performance:
+164.81%
1-Day Range:
$7.02
$7.22
1-Week Range:
$4.81
$7.22
52-Week Range:
$2.67
$7.22
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
7.15 | 1.97B | 3.49M | -663.48M | -115.08M | -2.2387 |
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 121.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
678.94 | 69.66B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
857.97 | 53.99B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
179.18 | 39.21B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.15 | 37.27B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
AtaiBeckley (ATAI) Agrees To Eli Lilly Buyout With Milestone Upside For Shareholders - simplywall.st
Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today? - Stocktwits
Eli Lilly (LLY.US) invests $3.8 billion to enter the psychedelic drug sector! Acquires AtaiBeckley (ATAI.US) with a 26% premium - Bitget
AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly - Yahoo Finance UK
Why AtaiBeckley Stock Soared Today - The Motley Fool
Are ATAI, FHB, PATK Obtaining Fair Deals for their Shareholders? - Morningstar
Why AtaiBeckley Stock Soared Today - The Motley Fool
Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom - drugdiscoverytrends.com
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion - The Motley Fool
Lilly to enter psychedelics field with $3.8B AtaiBeckley buy - FirstWord PHARMA
Lilly to buy psychedelic-drug firm AtaiBeckley - Chemical & Engineering News
Nasdaq slides as chip selloff drags Wall Street lower - Proactive financial news
Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drug - RAPS
Eli Lilly Buys AtaiBeckley in $3.8 Billion Deal - TradingView
AtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyout - TradingView
Market movers: AtaiBeckley, UnitedHealth Group, Abbott Laboratories, Medicus Pharma… - Proactive financial news
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of AtaiBeckley Inc. (NASDAQ: ATAI) - Morningstar
AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline - Seeking Alpha
Eli Lilly Acquires Psychedelics Specialist AtaiBeckleyWhat Investors Should Know (LLY) - Seeking Alpha
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug - 24/7 Wall St.
Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition - MedCity News
Pharma giant Eli Lilly enters psychedelics space with AtaiBeckley takeover - Mugglehead Investment Magazine
Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion - marketscreener.com
AtaiBeckley (ATAI) Sees 32.9% Surge in Stock Price - GuruFocus
Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition - International Business Times
Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock - Barchart.com
Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover - Pharmaceutical Technology
Lilly acquiring firm developing psychedelic depression treatments for up to $3.8M - Inside INdiana Business
Eli Lilly buys psychedelic drugs company AtaiBeckley for $3.8bn - The Times
Latham & Watkins Represents AtaiBeckley in Sale to Lilly - Latham & Watkins LLP
Why Is GH Research Stock Trading Higher on Thursday? - Benzinga
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics - BioPharma Dive
Shareholder Alert: Ademi LLP investigates whether AtaiBeckley Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker - Advisor Perspectives
ATAI-dyed Lilly tees up in psychedelics, finds $3.8B fit - BioWorld News
Eli Lilly Acquires AtaiBeckley for $3.8B - AllSci
Eli Lilly agrees to $3.8B psychedelic buy - Axios
Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion - Yahoo Finance Singapore
Halper Sadeh LLC is Investigating Whether ATAI, CCRN, NUVL are Obtaining Fair Deals for their Shareholders - GlobeNewswire
AtaiBeckley Inc (ATAI:UW): Stock Price, Quote and News - BNN Bloomberg
Eli Lilly to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion - qz.com
Lilly enters psychedelic drug race with up to US$3.8 billion AtaiBeckley deal - BNN Bloomberg
Eli Lilly deal to buy AtaiBeckley boosts psychedelic stocks - Seeking Alpha
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - KELO-AM
Lilly confirms arrival of new psychedelic age with $3.8 billion AtaiBeckley buy - The Pharma Letter
AtaiBeckley (ATAI) Surges Over 31% to Reach $7.05 - GuruFocus
AtaiBeckley (NASDAQ: ATAI) stock jumps on Lilly deal as market discounts milestones - TechStock²
Eli Lilly to Acquire AtaiBeckley for $2.8 Billion - Pharmaceutical Executive
Eli Lilly and Company entered into an Agreement and Plan of Merger to acquire AtaiBeckley Inc. from Apeiron Investment Group Limited and others. - marketscreener.com
Watch Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion - Bloomberg.com
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday - Benzinga
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):